Glucopeptides derived from myelin‐relevant proteins and hyperglucosylated nontypeable Haemophilus influenzae bacterial adhesin cross‐react with multiple sclerosis specific antibodies: A step forward in the identification of native autoantigens in multiple sclerosis

Multiple sclerosis (MS) is an inflammatory and autoimmune disorder, in which an antibody‐mediated demyelination mechanism plays a critical role. We prepared two glucosylated peptides derived from the human myelin proteins, that is, oligodendrocyte‐myelin glycoprotein (OMGp) and reticulon‐4 receptor (RTN4R), selected by a bioinformatic approach for their conformational homology with CSF114(Glc), a designed β‐turn antigenic probe derived from myelin oligodendrocyte glycoprotein (MOG), a glycoprotein present in the CNS. This synthetic antigen is specifically recognized by antibodies in sera of MS patients. We report herein the antigenic properties of these peptides, showing, on the one hand, that MS patient antibodies recognize the two glucosylated peptides and, on the other hand, that these antibodies cross‐react with CSF114(Glc) and with the previously described hyperglucosylated nontypeable Haemophilus influenzae bacterial adhesin protein HMW1ct(Glc). These observations point to an immunological association between human and bacterial protein antigens, underpinning the hypothesis that molecular mimicry triggers the breakdown of self‐tolerance in MS and suggesting that RTN4R and OMGp can be considered as autoantigens.

[1]  A. Papini,et al.  Selective Capture of Anti‐N‐glucosylated NTHi Adhesin Peptide Antibodies by a Multivalent Dextran Conjugate , 2021, Chembiochem : a European journal of chemical biology.

[2]  A. Bar-Or,et al.  Oligodendrocyte myelin glycoprotein as a novel target for pathogenic autoimmunity in the CNS , 2020, Acta Neuropathologica Communications.

[3]  V. Morra,et al.  A Multiple N-Glucosylated Peptide Epitope Efficiently Detecting Antibodies in Multiple Sclerosis , 2020, Brain sciences.

[4]  Frank Wien,et al.  BeStSel: a web server for accurate protein secondary structure prediction and fold recognition from the circular dichroism spectra , 2018, Nucleic Acids Res..

[5]  David H. Miller,et al.  Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria , 2017, The Lancet Neurology.

[6]  B. Imperiali,et al.  Antibodies from multiple sclerosis patients preferentially recognize hyperglucosylated adhesin of non-typeable Haemophilus influenzae , 2016, Scientific Reports.

[7]  O. Lequin,et al.  Antibody Recognition in multiple sclerosis and rett syndrome using a collection of linear and cyclic N‐glucosylated antigenic probes , 2015, Biopolymers.

[8]  M. Reindl,et al.  Antibody biomarkers in CNS demyelinating diseases – a long and winding road , 2015, European journal of neurology.

[9]  J. Fraussen,et al.  Targets of the humoral autoimmune response in multiple sclerosis. , 2014, Autoimmunity reviews.

[10]  E. Novellino,et al.  Designed glucopeptides mimetics of myelin protein epitopes as synthetic probes for the detection of autoantibodies, biomarkers of multiple sclerosis. , 2012, Journal of medicinal chemistry.

[11]  Robert H Miller,et al.  Oligodendrocyte differentiation and myelination defects in OMgp null mice , 2011, Molecular and Cellular Neuroscience.

[12]  Jeffrey A. Cohen,et al.  Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.

[13]  Pascal G. P. Martin,et al.  FAN (factor associated with neutral sphingomyelinase activation), a moonlighting protein in TNF‐R1 signaling , 2010, Journal of leukocyte biology.

[14]  A. Ascherio,et al.  Primary infection with the Epstein‐Barr virus and risk of multiple sclerosis , 2010, Annals of neurology.

[15]  E. Novellino,et al.  Designed glycopeptides with different beta-turn types as synthetic probes for the detection of autoantibodies as biomarkers of multiple sclerosis. , 2008, Journal of medicinal chemistry.

[16]  Roland Martin,et al.  Multiple sclerosis: a complicated picture of autoimmunity , 2007, Nature Immunology.

[17]  B. Kolesińska,et al.  A convenient microwave-assisted synthesis of N-glycosyl amino acids , 2007 .

[18]  E. Novellino,et al.  Conformation-activity relationship of designed glycopeptides as synthetic probes for the detection of autoantibodies, biomarkers of multiple sclerosis. , 2006, Journal of medicinal chemistry.

[19]  L. Santoro,et al.  The glycopeptide CSF114(Glc) detects serum antibodies in multiple sclerosis , 2005, Journal of Neuroimmunology.

[20]  E. Novellino,et al.  An N-glucosylated peptide detecting disease-specific autoantibodies, biomarkers of multiple sclerosis. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Christian Andres,et al.  Oligodendrocyte myelin glycoprotein (OMgp): evolution, structure and function , 2004, Brain Research Reviews.

[22]  A. Fournier,et al.  Structure and axon outgrowth inhibitor binding of the Nogo‐66 receptor and related proteins , 2003, The EMBO journal.

[23]  S. Strittmatter,et al.  The Nogo-66 receptor: focusing myelin inhibition of axon regeneration , 2003, Trends in Neurosciences.

[24]  S. Strittmatter,et al.  Localization of Nogo-A and Nogo-66 Receptor Proteins at Sites of Axon–Myelin and Synaptic Contact , 2002, The Journal of Neuroscience.

[25]  A. Fournier,et al.  Identification of a receptor mediating Nogo-66 inhibition of axonal regeneration , 2001, Nature.

[26]  E. Kaiser,et al.  Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. , 1970, Analytical biochemistry.

[27]  M. Bonache,et al.  Posttranslationally modified peptides efficiently mimicking neoantigens: a challenge for theragnostics of autoimmune diseases. , 2010, Biopolymers.

[28]  M. V. Van Regenmortel,et al.  Antigenicity and immunogenicity of synthetic peptides. , 2001, Biologicals : journal of the International Association of Biological Standardization.

[29]  W. L. Benedict,et al.  Multiple Sclerosis , 2007, Journal - Michigan State Medical Society.